An analysis presented at Digestive Diseases Week in San Diego, CA, shows bezlotoxumab reduces rates of recurrent C. diff infection in high-risk patients.
An analysis presented at Digestive Diseases Week in San Diego, CA, shows bezlotoxumab reduces rates of recurrent C. diff infection in high-risk patients.
